Figure 1From: Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma Schematic illustrating the clinical and laboratory presentation of our patient. Proteinuria in month 5 was measured on a spot urine sample. Proteinuria in months 6 and 8 was estimated from a 24-hour urine collection. Black arrows reflect carfilzomib administration (20 mg/m2 in month 4, and 27 mg/m2 in month 5).Back to article page